Chicago Partners Investment Group LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 9.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,714 shares of the company’s stock after purchasing an additional 1,144 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Johnson & Johnson were worth $1,653,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Beach Investment Management LLC. lifted its position in Johnson & Johnson by 1,256.6% in the second quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock valued at $37,921,000 after buying an additional 265,518 shares during the last quarter. TD Asset Management Inc. lifted its position in Johnson & Johnson by 4.0% in the second quarter. TD Asset Management Inc. now owns 3,026,397 shares of the company’s stock valued at $400,362,000 after buying an additional 115,651 shares during the last quarter. Advisor Partners LLC lifted its position in Johnson & Johnson by 8.6% in the second quarter. Advisor Partners LLC now owns 60,635 shares of the company’s stock valued at $8,021,000 after buying an additional 4,805 shares during the last quarter. Armbruster Capital Management Inc. lifted its position in Johnson & Johnson by 13.5% in the second quarter. Armbruster Capital Management Inc. now owns 4,347 shares of the company’s stock valued at $575,000 after buying an additional 518 shares during the last quarter. Finally, Financial Advisory Service Inc. lifted its position in Johnson & Johnson by 0.9% in the second quarter. Financial Advisory Service Inc. now owns 14,971 shares of the company’s stock valued at $1,981,000 after buying an additional 131 shares during the last quarter. 67.23% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have commented on JNJ. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 target price on the stock in a research report on Thursday. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 target price on the stock. in a research report on Thursday. TheStreet cut shares of Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Jefferies Group set a $161.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Finally, Citigroup reduced their price target on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $144.58.
In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.22% of the stock is currently owned by corporate insiders.
Shares of JNJ stock traded down $2.61 during trading hours on Friday, reaching $128.10. 6,399,310 shares of the stock were exchanged, compared to its average volume of 7,081,583. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32. The firm has a market capitalization of $343,679.78, a price-to-earnings ratio of 17.55, a PEG ratio of 2.04 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the prior year, the firm earned $1.58 earnings per share. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. equities analysts forecast that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
WARNING: “Chicago Partners Investment Group LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/johnson-johnson-jnj-stake-increased-by-chicago-partners-investment-group-llc.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.